Saliva Interleukin-6 in patients with inflammatory bowel disease

被引:58
作者
Nielsen, AA
Nielsen, JN
Schmedes, A
Brandslund, I
Hey, H
机构
[1] Vejle Cty Hosp, Dept Clin Biochem, DK-7100 Vejle, Denmark
[2] Vejle Cty Hosp, Dept Med Gastroenterol, DK-7100 Vejle, Denmark
[3] Univ So Denmark, Inst Hlth Res, Odense, Denmark
关键词
inflammatory bowel disease; Interleukin-6; saliva;
D O I
10.1080/00365520510023774
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective. The inflammatory bowel diseases ( IBD), Crohn's disease ( CD) and ulcerative colitis ( UC) are chronic inflammatory conditions that affect the gastrointestinal tract. In regulation of this inflammatory process, Interleukin- 6 ( IL-6) has a major role. Overproduction of IL- 6 by immunocompetent cells contributes to development of the inflammatory condition. Elevated levels of IL- 6 in saliva could be expected, because the saliva- producing cells are part of the digestive system. Material and methods. IL- 6 concentrations in saliva and plasma were studied in patients with CD ( n = 15), UC ( n = 7) and reference persons ( RP) ( n = 19) by use of an ELISA method. Results. A significant difference in saliva IL- 6 concentration between CD patients ( median 16.9 ng/ L; p < 0.05) and RP ( median 6.3 ng/ L) was found. A significant difference in plasma IL- 6 concentration between CD ( median 10.3 ng/ L; p < 0.001) or UC ( median 7.8 ng/ L; p < 0.001) and RP ( median 0.8 ng/ L) was observed. In patients with CD, plasma IL- 6 correlated significantly with C- reactive protein ( CRP) as well as albumin. In patients with UC, saliva IL- 6 and plasma IL- 6 correlated significantly with AI ( activity index) scores as well as albumin. In patients with UC, a significant correlation between the saliva and plasma IL- 6 concentrations was found. Conclusions. IL- 6 was found in saliva in patients with IBD, documenting the general involvement of the gastrointestinal tract extending to the mouth cavity, and measuring IL- 6 may be an additional method for evaluating and monitoring the disease activity.
引用
收藏
页码:1444 / 1448
页数:5
相关论文
共 17 条
[1]  
BASU MK, 1980, CLIN GASTROENTEROL, V9, P307
[2]   THE ACUTE-PHASE RESPONSE [J].
BAUMANN, H ;
GAULDIE, J .
IMMUNOLOGY TODAY, 1994, 15 (02) :74-80
[3]   Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-α and interferon-γ, and has potential in the treatment of arthritis [J].
Bendtzen, K ;
Hansen, PR ;
Rieneck, K .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 134 (01) :151-158
[4]  
BEST WR, 1976, GASTROENTEROLOGY, V70, P439
[5]   SERUM LEVELS OF C-REACTIVE PROTEIN IN CROHNS-DISEASE AND ULCERATIVE-COLITIS [J].
FAGAN, EA ;
DYCK, RF ;
MATON, PN ;
HODGSON, HJF ;
CHADWICK, VS ;
PETRIE, A ;
PEPYS, MB .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1982, 12 (04) :351-359
[6]   Elevated cell-associated levels of interleukin 1 beta and interleukin 6 in inflamed mucosa of inflammatory bowel disease [J].
GrottrupWolfers, E ;
Moeller, J ;
Karbach, U ;
MullerLissner, S ;
Endres, S .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1996, 26 (02) :115-122
[7]  
Hirano T, 1998, Int Rev Immunol, V16, P249
[8]   SERUM INTERLEUKIN-6 IS RELATED TO DISEASE-ACTIVITY BUT NOT DISEASE SPECIFICITY IN INFLAMMATORY BOWEL-DISEASE [J].
HOLTKAMP, W ;
STOLLBERG, T ;
REIS, HE .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 20 (02) :123-126
[9]   How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? [J].
Jorgensen, LGM ;
Fredholm, L ;
Petersen, PH ;
Hey, H ;
Munkholm, P ;
Brandslund, I .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2005, 43 (04) :403-411
[10]  
Kmiez Zbigniew, 1998, Archivum Immunologiae et Therapiae Experimentalis, V46, P143